Plaque psoriasis (PsO) is an inflammatory condition characterized by inflamed scaly patches of skin all over the body and is associated with lowered quality of life and serious comorbidities. Several biologics for the treatment of PsO have been reimbursed in Canada in the past decade, spanning different mechanisms of action and annual costs. Many of these biologics have expired data exclusivity status. Following the Environmental Scan for biologics in PsO (ES0357), a utilization study is warranted to study the patterns of use of these biologics across public drug plans to support potential formulary management discussions.
This analysis will collect claims data for biologics across public drug plans from the past several years. Market shares and opportunity costs of delayed biosimilar uptake for drugs with expired exclusivity status will be evaluated.
Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of the final reports varies and expected completion dates may change. Find out more about Projects in Progress.
The “Projects in Progress” page on the CADTH website is updated on a seven- to eight-day cycle. Please be advised that there may be overlap between when a new report is posted online and when the section is updated. View our current Projects in Progress.